Traditional HER2-directed therapies, such as trastuzumab and pertuzumab, which are highly effective in HER2-amplified breast cancer, have shown limited efficacy in HER2-mutant NSCLC (29, 30). Here, ERBB2 is linked to breast carcinoma.